1例卵巢癌患者使用贝伐珠单抗联合TC化疗方案致血小板减少症的药学监护

Pharmacological care of a patient with ovarian cancer using bevacizumab in combination with a TC chemotherapy regimen due to thrombocytopenia

摘要:

目的 通过观察1例卵巢癌患者接受贝伐珠单抗联合TC化疗方案致血小板减少症的临床特征,探讨治疗方案和药学监护模式。方法 临床药师对1例卵巢癌患者使用贝伐珠单抗联合TC化疗方案致血小板减少症的临床资料进行病情分析,并查阅文献,优化治疗方案,协助医生共同对患者进行药学监护。结果 在临床药师的指导下,患者接受升血小板治疗后症状得到改善,血小板计数指标上升至正常水平。结论 临床药师在患者治疗期间为其提供专业药学监护,协助临床医生制定个体化治疗方案,有助于保障患者用药安全,促进合理用药。

Abstract:

Objective To observe the clinical characteristics of ovarian cancer patients receiving bevacizumab combined with TC chemotherapy regimen resulting in thrombocytopenia, to explore the therapeutic regimen and pharmacological supervision. Methods Clinical pharmacists analyzed the clinical data of one ovarian cancer patient using bevacizumab combined with TC chemotherapy regimen resulting in thrombocytopenia, and reviewed the literature to optimize the treatment plan, and assisted the doctors to jointly provide pharmacological supervision for the patient. Results With supervision of clinical pharmacists, the patient was improved after receiving platelet elevating therapy, and the platelet count indexes rose to the normal level. Conclusion Clinical pharmacists provide pharmacological monitoring for patients during their treatment from a professional perspective, and assist clinicians in formulating individualized treatment plans, which helps to ensure the safety of patients" medication and promote the rational use of medication.